Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis

Peter J Ruane MD Inc, Los Angeles

University of California Davis, Sacramento

Midway Immunology & Research Center, LLC, Ft. Pierce

Infectious Disease Consultants, M.D., P.A. d/b/a Orlando Immunology Center, Orlando

Triple O Research Institute PA, West Palm Beach

Medical College of Georgia, Augusta

Infectious Disease Specialists of Atlanta, Decatur

Mercer University School of Medicine, Macon

The Research Institute, Springfield

Henry Ford Health System, Detroit

Prime Health Care Services - St Michael's LLC d/b/a Saint Michael's Medical Center, Newark

University of North Carolina at Chapel Hill / UNC School of Medicine, Chapel Hill

Duke University, Durham

Wake Forest University Baptist Medical Center, Winston-Salem

University of Cincinnati Med Center, Cincinnati

MetroHealth Medical Center IRB, Cleveland

North Texas Infectious Diseases Consultants, Dallas

Trinity Health and Wellness Center, Fort Worth

Gordon E. Crofoot MD PA, Houston

Otto Wagner Spital, Vienna

Hopital Henri Mondor, Créteil

CHU de Nice-l Archet, Nice

Hopital Bichat-Claude Bernard, Paris

Hopital Saint Louis, Paris

Centre Hospitalier de Tourcoing, Tourcoing

Klinikum rechts der Isar, TUM, München